David R. Lally, MD

David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.

David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.

David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.

David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.

David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.

A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.

A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.

An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.

Jayanth Sridhar, MD, Nancy M. Holekamp, MD, FASRS, and David R. Lally, MD, share their thoughts on measuring visual changes to determine how their patients’ geographic atrophy is progressing.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp provide an overview of age-related macular degeneration and risk of developing geographic atrophy (GA).

Retina specialists share advice and practice pearls regarding the management of DME and neovascular AMD, including counseling patients about the importance of healthy lifestyles.

Carl D. Regillo, MD, FACS, leads a discussion with retina specialists about the future of care for AMD and DME, including tyrosine kinase inhibition and gene therapy.

Retina specialists discuss concerns and apprehensions that both physicians and patients may feel towards newer modalities and delivery mechanisms for the treatment of AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, talk about important data that has awaited for several newer and investigational therapies for DME and AMD.

Carl D. Regillo, MD, FACS, and Michael A. Klufas, MD, discuss the possible impact of biosimilars and share important considerations regarding cost and safety.